Kornitzer Capital Management Inc. KS Purchases 13,500 Shares of Omnicell, Inc. $OMCL

Kornitzer Capital Management Inc. KS lifted its position in Omnicell, Inc. (NASDAQ:OMCL) by 91.8% in the third quarter, HoldingsChannel.com reports. The firm owned 28,200 shares of the company’s stock after acquiring an additional 13,500 shares during the period. Kornitzer Capital Management Inc. KS’s holdings in Omnicell were worth $859,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Lazard Asset Management LLC boosted its stake in Omnicell by 3.8% during the second quarter. Lazard Asset Management LLC now owns 1,708,345 shares of the company’s stock worth $50,225,000 after buying an additional 62,733 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Omnicell by 1.3% during the 2nd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,423,604 shares of the company’s stock worth $41,854,000 after acquiring an additional 17,680 shares during the period. Geode Capital Management LLC boosted its position in shares of Omnicell by 2.6% during the 2nd quarter. Geode Capital Management LLC now owns 1,195,896 shares of the company’s stock valued at $35,163,000 after acquiring an additional 30,678 shares in the last quarter. Qube Research & Technologies Ltd increased its stake in Omnicell by 38.4% in the second quarter. Qube Research & Technologies Ltd now owns 653,971 shares of the company’s stock valued at $19,227,000 after acquiring an additional 181,394 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. increased its stake in Omnicell by 1.7% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 461,506 shares of the company’s stock valued at $13,568,000 after acquiring an additional 7,518 shares during the period. 97.70% of the stock is owned by institutional investors.

Omnicell Stock Down 1.8%

Shares of OMCL opened at $49.04 on Thursday. The company has a market capitalization of $2.20 billion, a P/E ratio of 114.05, a PEG ratio of 5.32 and a beta of 0.77. Omnicell, Inc. has a one year low of $22.66 and a one year high of $55.00. The business’s 50 day simple moving average is $44.98 and its 200-day simple moving average is $36.20. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.44 and a quick ratio of 1.21.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Omnicell in a report on Thursday, January 22nd. Benchmark raised their target price on Omnicell from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. UBS Group set a $53.00 price target on Omnicell in a research note on Friday, January 16th. KeyCorp upgraded Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price objective for the company in a research note on Wednesday, January 7th. Finally, Zacks Research cut Omnicell from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 9th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $48.57.

Insider Activity at Omnicell

In other news, EVP Corey J. Manley sold 6,106 shares of the firm’s stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $49.90, for a total value of $304,689.40. Following the completion of the sale, the executive vice president directly owned 91,674 shares in the company, valued at approximately $4,574,532.60. This trade represents a 6.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 2.52% of the company’s stock.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.